Osteologix, Inc has received a Notice of Allowance from the US Patent and Trademark Office for its US Patent Application Number 11/269,289 titled 'Water-Soluble Strontium Salts for Use in Treatment of Cartilage and/or Bone Conditions' reporting allowance of claims covering the treatment of osteoporosis and related bone conditions using NB S101 (strontium malonate), the company's lead osteoporosis drug candidate. The company expects the patent will issue in the second half of 2009; the patent's 20-year term would expire in 2024. The company has a number of other pending patent applications covering various aspects of the NB S101 drug programme including composition, manufacturing and method of use patent applications.

"Based on the Notice of Allowance and the claims allowed by the USPTO, we believe the intellectual property protections established by this US patent allowance, coupled with our recently upheld European equivalent, will significantly enhance our ability to finalize strong development collaborations with potential partners to complete the phase-III development of NB S101 in osteoporosis," stated Philip J Young, president and chief executive officer of Osteologix.

NB S101 (strontium malonate) is a novel dual acting bone agent, or DABA, which clinical studies demonstrate, significantly improves bone density.

Osteologix is a specialty biopharmaceutical company committed to improving the health of those afflicted with musculoskeletal diseases, such as osteoporosis.